An IPPF News Site

  • Principia Biopharma Reports Positive PRN1008 Phase 2 Top-Line Results and Initiates Phase 3 Pemphigus Program

    Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced positive top-line data from the completed open-label Phase 2 trial of PRN1008 in patients with pemphigus (including both pemphigus vulgaris (PV) and pemphigus foliaceus (PF)) and the ...

  • Aimee Payne and Nicola Mason Receive NIH Award

    Transformative Research Award Will Support Further Pemphigus Research Nicola J. Mason, BVetMed, PhD, associate professor of Medicine and Pathobiology at the School of Veterinary Medicine at the University of Pennsylvania, and Aimee S. Payne, MD, PhD, the Albert M. Kligman Associate Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, have ...

  • Bertilimumab Granted Fast Track Designation for the Treatment of Bullous Pemphigoid

    The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to bertilimumab for the treatment of bullous pemphigoid. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of drugs to treat serious conditions that are unmet medical needs.

  • Bertilimumab Granted Orphan Drug Designation for the Treatment of Bullous Pemphigoid

    The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to bertilimumab for the treatment of bullous pemphigoid.

  • Self-Care: Comfort Techniques and Dressings

    Pemphigus and pemphigoid (P/P) patients may agree that in the early months of their condition it is a very painful and difficult time. However, the following suggestions may be helpful like learning how to care for our skin in terms of taking and applying topical medications, cleansers, moisturizers, dressings, and staying comfortable.

  • Rituxan Receives FDA Approval to Treat Pemphigus Vulgaris

    On Thursday, June 7th, the FDA approved Rituxan for the treatment of adults with moderate to severe pemphigus vulgaris (PV). Rituxan is the first biologic therapy approved by the FDA for PV and the first major advancement in the treatment of PV in more than 60 years.

  • Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus

    Syntimmune recently announced positive preliminary results from its phase 1b proof-of-concept trial of SYNT001 in pemphigus vulgaris and foliaceus patients. It’s exciting for the IPPF to share good news related to research and treatments. The full press release from Syntimmune can be found here. The following is an excerpt:   Syntimmune, Inc., a clinical-stage biotechnology company developing ...

  • Strategies for Managing Pemphigus and Pemphigoid

    It can be difficult to accept the news of a lifelong chronic disease. It may be easier to understand the diagnosis of appendicitis when a procedure is needed, or medication to treat a cold, or the need to use crutches for a couple of months because of a broken bone. But accepting a disease like ...

  • FDA Grants Priority Review For Genentech’s Rituxan® (Rituximab) For Pemphigus Vulgaris

    Genentech recently announced an important FDA decision that could potentially impact future treatment options for pemphigus. Here at the IPPF, it’s especially exciting when we get to share good news related to research and treatments. The full press release from Genentech can be found here. The following is an excerpt: The U.S. Food and Drug Administration (FDA) ...

  • Resilience

    You don’t have to be a Navy SEAL, firefighter, or an NFL football player to be resilient. Resilience is a common trait that you can build upon by developing certain skills. Research has shown that while some people are naturally more resilient, these behaviors can also be learned. Here are some techniques to foster your ...